vTv Therapeutics Inc.

Equities

VTVT

US9183852048

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
26.96 ^USD	+4.64%		+12.17%	+134.48%

Mar. 14	VTv Therapeutics Inc. Announces Board Changes	CI
Mar. 13	VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

December 22, 2023 at 04:26 pm EST

vTv Therapeutics Inc. announced on December 18, 2023, Chandresh Harjivan resigned as a member of the board of directors (the ?Board?) of the Company to pursue other opportunities. Mr. Harjivan?s resignation was not because of a disagreement on any matter relating to the Company?s operations, policies or practices.

Latest news about vTv Therapeutics Inc.

VTv Therapeutics Inc. Announces Board Changes	Mar. 14	CI
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
VTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes	Mar. 04	CI
Top Midday Gainers	Feb. 28	MT
VTv Therapeutics Inc. Announces Board Changes	Feb. 28	CI
VTv Therapeutics Inc. announced that it has received $50.961457 million in funding from JDRF T1D Fund, Samsara BioCapital LLC and another investors	Feb. 26	CI
Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors	Dec. 22	CI
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer	Nov. 02	CI
North American Morning Briefing : China Trouble -2-	23-08-18	DJ
VTv Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
VTv Therapeutics Says Cantex Pharmaceuticals Received IP License for Azeliragon	23-06-16	MT
Cantex Pharmaceuticals Receives US Patent Covering vTv Therapeutics' Azeliragon	23-05-24	MT
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (VTVT) VTV THERAPEUTICS Reports Q4 Revenue $9,000	23-03-06	MT
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-06	CI
VTv Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	23-03-05	CI
VTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel	23-02-01	CI
VTv Therapeutics Names Steven Tuch Finance Chief	22-12-13	MT
VTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer	22-12-13	CI
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Northland Securities Raises Price Target on vTv Therapeutics to $2 From $1.50, Maintains Outperform Rating	22-08-18	MT
VTv Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI

Chart vTv Therapeutics Inc.

Duration

Period

More charts

Company Profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
VTV THERAPEUTICS INC.	+134.48%	65.6M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs